Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND 11314): a Phase I/II Clinical Trial.
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2018
At a glance
- Drugs Tagraxofusp (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 May 2018 Status changed from active, no longer recruiting to completed.
- 02 Sep 2016 Status changed from completed to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History